400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR2100049535
尚未开始
/
/
/
2021-08-02
/
/
Hypertension
Social media-delivered care for improving hypertension management in the Tibetan plateau: the WECARE randomised controlled trial protocol
Social media-delivered care for improving hypertension management in the Tibetan plateau: the WECARE randomised controlled trial protocol
6149
The aim of this study is to evaluate the effectiveness of a social media-delivered comprehensive hypertension management programme in patients with uncontrolled hypertension.
随机平行对照
其它
Following the provision of written informed consent, participants will be randomised in a 1:1 fashion to the WECARE group, or a usual care group, using central randomisation, with variable block size and stratification by gender, age and baseline treatment status (no medication/medical therapy).
To maintain blinding of study personnel involved in follow-up assessments to group allocation, participants will be informed of their allocation via a WeChat message sent after leaving the trial sites.
China Medical Board
/
230
/
2021-06-01
2024-05-31
/
Individuals will be eligible if they are WeChat users, have an operating smartphone, and are aged between 18 or over. Have had a medical history of hypertension documented for six or more months and have at least two measures in the last three months indicating poor control. Participants will be also required to have sufficient Chinese or Tibetan language proficiency, as well as digital literacy in using WeChat and the internet, to enable WeChat-based health education and communication with the WECARE team.;
请登录查看Individuals will be excluded if they are currently receiving any mHealth-based hypertension management programme, have no internet access at their place of residence, or are unable to operate a smartphone, or Bluetooth-enabled BP monitor for the purpose of the trial (e.g., vision, hearing, cognitive or dexterity impairment). Other exclusion criteria include the following: a known cause of secondary hypertension; acute coronary syndrome, coronary revascularisation or stroke, within the past three months; heart failure; or receiving haemodialysis or chemotherapy.;
请登录查看China Medical Board
6150
英百瑞生物2025-12-05
艾力斯医药科技2025-12-05
神曦生物NeuExcell2025-12-05
科望医药2025-12-05
宠药生态圈2025-12-05
丁香园 Insight 数据库2025-12-05
佰傲谷BioValley2025-12-05
药精通Bio2025-12-05
医药观澜2025-12-05
贝达药业2025-12-05